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| INTRODUC TI ON
Pancreatic cancer (PanC) is one of the most lethal solid malignancies, and PanC is the fourth most common cause of cancer deaths in the USA, 1 responsible for an estimated 44 330 deaths in 2018. 2, 3 The poor prognosis of pancreatic ductal adenocarcinoma relates to the advanced disease stage at the time of diagnosis and its profound resistance to therapies, 4, 5 because metastatic PanC is commonly present by the time of initial diagnosis as a result of a lack of effective screening tests. To reduce the enormous death toll related to this cancer, an enhanced screening method among the at-risk populations is urgently needed. However, identification of the at-risk populations requires highly effective biomarkers that predict PanC risk. 6 Genetic and environmental factors for the etiology of PanC remains only partially elucidated. Risk factors for PanC cancer identified in epidemiological studies include cigarette smoking, increased body mass index, heavy alcohol consumption, and a diagnosis of diabetes mellitus. 7 Recently, investigations have reported a number of genetic factors or susceptibility genes or loci for PanC risk.
PanC high-penetrance genes include BRCA1, BRCA2, TP53, CDKN2A, APC, STK11 and MMR genes, whereas low-penetrance risk loci include chromosome 9q34 (in the ABO blood group gene), 1q32.1 (in NR5A2), 5p15.33 (in the CLPTM1L-TERT gene region), 16q23.1 (BCAR1), 13q12.2 (PDX1), 22q12.1 (ZNRF3), 1p36.33 (NOC2L), and 22q13.1 (PDGFB). [7] [8] [9] [10] [11] However, these established genes or loci could explain only 20%-30% of PanC risk, including 5%-10% of the familial aggregation of PanC. In the remaining 80%-85% of sporadic patients, there has been limited success in resolving the genetic architecture of PanC.
8
The nuclear factor E2-related factor 2 (NFE2L2 or NRF2) pathway is one of the major signaling cascades involved in cell defense and survival against endogenous and exogenous stress. 12 NRF2
mediates the expression of more than 100 oxidative stress-related genes. These cytoprotective genes all contain the cis-regulatory element sequence antioxidant response element (5′-GTGACnnnGC-3′)
in their promoter regulatory regions for NRF2 binding. 12 It has been
shown that constitutive activation of NRF2 in cancer cells increases the expression of cytoprotective genes and, consequently, enhances proliferation via metabolic reprogramming and inhibition of apoptosis. 13 A growing number of studies have shown that aberrant activation of the transcription factor NRF2 promotes PanC tumorigenesis, likely by regulating the expression of a vast array of genes. [14] [15] [16] A high rate of somatic mutations in NRF2-KEAP1 pathway genes has been observed in several types of carcinoma in TCGA database, 17 which highlights the roles of genes in the NRF2 pathway as cancer driver genes with potential clinical ramifications. Several polymorphisms in NRF2 pathway genes have recently been identified to be associated with cancer risk, including lung adenocarcinoma and breast cancer. 18, 19 Therefore, a complete understanding of the germline changes in PanC is essential to identify potential susceptibility.
In the present study, we aimed to identify novel susceptibility loci in NRF2 pathway genes for their associations with PanC risk by using a pathway-based approach to leverage the published PanC GWAS datasets. Figure S1 ). Details of cases (individuals with pancreatic ductal adenocarcinoma) and controls have been previously described. 11, 20, 21 Distributions of demographic characteristics between pancreatic cancer cases and controls are shown in Table S1 . Both the PanScan and PanC4 GWAS datasets are available through dbGAP with permission from NCI of NIH to use the datasets with the accession numbers of phs000206.v5.p3 and phs000648.v1.p1, respectively.
| MATERIAL S AND ME THODS

| Study participants
Each study obtained written informed consent from study participants and approval from its Institutional Review Board (IRB) including IRB certification permitting data-sharing in accordance with the NIH Policy for Sharing of Data Obtained in NIH Supported or both rs3124761 T and rs17458086 C alleles were associated with increased mRNA expression levels of SLC2A6 and SLC2A13, respectively (P < 0.05). In conclusion, genetic variants in NRF2 pathway genes could play a role in susceptibility to PanC, and further functional exploration of the underlying molecular mechanisms is warranted.
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Conducted GWAS. The present study protocol, which had been laid down in accordance with the ethical standards in the 1964
Declaration of Helsinki and its later amendments, was approved by the Duke University Health System Institutional Review Board and strictly followed.
| Gene selection, genotyping, and imputation
The term "NRF2 pathway" was searched in GeneCards: The Human Gene Database (https://www.genecards.org/). Overall, 164 genes located on autosomal chromosomes were selected (details are presented in Table S2 ). GWAS genotyping was done in accordance with the approach described previously. 
| Association analysis
In the single-locus analysis, we used a logistic regression model with adjustment for age, gender, and the top five principal components, which were selected from unconditional logistic regression analysis with the top 20 principal components from all three studies (Table   S3 ). An OR and its 95% CI were estimated by unconditional logistic regression analysis with PLINK 1.9 22 with a score test for the log additive genetic effect. A meta-analysis was further used on the results of a log-additive model of 31 583 SNP using the fixed-effects inverse-variance method based on β estimates and standard errors using Stata software (v.12; Stata Corp., College Station, TX, USA).
Cochran's Q statistics and I 2 were used to assess heterogeneity (Qtest P < 0.10 or I 2 > 50%).
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The FDR approach with a cut-off value of 0.15 was applied to control for multiple testing and to reduce the probability of falsepositive findings. 24, 25 The association between each SNP and PanC risk was evaluated with an additive genetic model.
The multivariable stepwise logistic regression model with a cutoff value of 0.05 was used to identify independent SNP. NUG of SNP with independent effects was used to assess the classification performance of the model. All individuals were also divided into a low-risk group (0-1 NUG) and a high-risk group (2-3 NUG) for additional analysis.
Moreover, Haploview v.4.2 was used to produce the Manhattan plot, and LocusZoom was used to construct the regional association plots by using the 1000 Genomes Project CEU dataset (phase I integrated release 3, March 2012), which were the same as previ- 
| In silico functional prediction and validation
We used four in silico tools of F-SNP (http://compbio.cs.queensu.
ca/F-SNP), 26 
| RE SULTS
| Single-locus analysis
Workflow of the present analysis is shown in Figure 1 . First, we carried out the single-locus analysis to estimate the associations be- and MAPK8 passed multiple testing corrections with an FDR <0.15
( Figure 2A ; Table 1 Figure S3 . All three SNP were from imputation and showed a relatively low heterogeneity among the three GWAS datasets (all Q-test P > 0.1 and I 2 < 25.0%).
| Genotype effect and the joint-effect of the three significant SNP
We then assessed the independent genotype effects and their joint effects of the three identified SNP in the presence of age, gender and the top five principal components in a multivariate stepwise logistic regression model. All three SNP remained significantly and independently associated with PanC risk (Table S4) . Specifically, the genotypes of SLC2A6 rs3124761 C/T, SLC2A13 rs17458086 T/C, and SLC5A3 rs1630747 A/C were significantly associated with PanC risk in the additive models (P < 0.0001, P = 0.004, and P = 0.002, respectively, Table 2 ). In dominant models, both the rs3124761 T allele and rs17458086 C allele carriers were at increased risk of PanC (OR = 1.19, 95% CI = 1.11-1.27, and P < 0.0001; OR = 1.36, 95% CI = 1.14-1.64, and P < 0.001), whereas the rs1630747 C allele was associated with reduced risk (OR = 0.89, 95% CI = 0.84-0.96, P = 0.001), compared with their corresponding wild-type alleles (Table 2) . In recessive models, the rs3124761 TT genotype carriers were at increased risk of PanC (OR = 1.28, 95% CI = 1.04-1.57, and P = 0.0191), whereas the rs1630747 CC genotype was associated with reduced risk (OR = 0.88, 95% CI = 0.77-0.99, P = 0.0433) compared with their corresponding wild-type genotypes (Table 2) .
We then combined the risk genotypes of rs3124761 CT+TT, rs17458086 TC+CC, and rs1630747 AA into a single genetic score NUG. The trend test indicated a significant association between an increased NUG and an increased risk of PanC (P < 0.0001, Table 3 ).
We also divided all individuals into a low-risk group (0-1 NUG) and a high-risk group (2-3 NUG) and found that PanC risk in high-risk individuals was greater than that among the low-risk group (OR = 1.26, 95% CI = 1.16-1.37, P < 0.0001, Table 3 ). As the difference in the distribution of age existed in each dataset (Table S1 ) and age is a known risk factor for PanC, we carried out subgroup analysis by age group (ie, <60, 60-70 and >70 years) and gender. It was found that the risk associated with high-risk NUG was most evident in the <60 years group (OR = 1.34, 95% CI = 1.15-1.56, P = 0.0002). There was no obvious difference between males and females. Additionally, there was no evidence for an interaction among and between these strata (P > 0.05, Table S5 ).
| Genotype and phenotype correlation analysis
Finally, we carried out in silico prediction for potential effects of the three SNP on mRNA expression levels preliminarily through the online tools (Table S6 ). All three SNP are located in intronic regions, but are also located in the enhancer region of histone H3 mono methyl K4 (H3k4me1) that marks active/poised enhancers and/ or in binding sites for DNase or transcription factors ( Figure 3A ,F, Figure S4A ).
We then assessed the effects of the three variants on the predicted TF-binding sites. It is notable that the three SNP are predicted to alter the ability to bind with some motifs, among which are rs3124761 T, rs17458086 C and rs1630747 C alleles that are predicted to disrupt the TF-binding motifs for the RARG, BCL2, and
Flowchart of the present study. eQTL, expression quantitative trait loci; FDR, false discovery rate; GTEx, Genotype-Tissue Expression; HWE, Hardy-Weinberg equilibrium; MAF, minor allele frequency; NRF2, nuclear factor erythroid2-related factor2; PC, pancreatic cancer; SNP, single nucleotide polymorphism; TCGA-PRAD, The Cancer Genome Atlas Prostate Adenocarcinoma ZN784 proteins, respectively ( Figure 3B ,G, Figure S4B ). This suggests that RARG, BCL2, and ZN784 binding motifs can be altered by rs3124761, rs17458086, and rs1630747, respectively, and thus change SLC2A6, SLC2A13, and SLC5A3 mRNA expression levels.
To substantiate the associations between the identified SNP and PanC risk, we evaluated correlations between SNP and mRNA expression levels of the corresponding genes in normal lymphoblastoid cell lines from 373 Europeans available from the 1000 Genomes Project. By using Student's t test or linear regression analysis of the logarithm transformed expression values (log2), we showed that the rs3124761 T allele (risk) was correlated with increased mRNA expression levels of SLC2A6 in either additive or dominant models (P = 0.0357 and 0.0129, respectively, Figure 3C ,D). We also found that the rs17458086 C (risk) allele was significantly correlated with higher mRNA expression levels of SLC2A13 compared with the T (protective) allele (P = 0.026 in both the additive model and the dominant model due to lack of CC homozygote ( Figure 3H,I ). eQTL results for SNP rs1630747 were not significant in these lymphoblastoid cell lines in either of the genetic models ( Figure S4C,D) .
We attempted to use data from the Genotype-Tissue Expression Project (GTEx) database (http://www.gtexp ortal.org/home/) and the data from 127 Europeans in the TCGA-PDAC Project to query the eQTL results and assessed the correlations. Imputation of the genotype of the three SNP based on the current quality control of these databases was not successful. In addition, we assessed the differences in mRNA expression levels of SLC2A6, SLC2A13, and SLC5A3 between adjacent normal pancreatic tissues and pancreatic tumor tissues from the Oncomine database. We found that compared with the expression in normal pancreatic tissues, both SLC2A6 and SLC2A13 mRNA levels in tumor tissues were significantly increased (P = 5.43 × 10 −4
and P = 0.027) ( Figure 3E ,J), whereas no statistical difference in SLC5A3 mRNA expression levels was found (P = 0.954) ( Figure S4E ).
| D ISCUSS I ON
In the present study of the NRF2-pathway-based approach analysis of published GWAS datasets, we identified 13 loci to be associated with PanC risk, including three novel loci (ie, SLC5A3 rs1630747, SLC2A13 rs17458086 and SLC2A6 rs3124761), which merit additional follow-up investigations for their functional mechanisms underlying the observed associations.
The first genetic variant rs3124761 to be addressed is located in the intron of SLC2A6 on Chr9q34. The rs3124761 T allele was 
TA B L E 3
Associations between the combined genetic score (NUG) and risk of pancreatic cancer region have been reported by a GWAS to be related to PanC susceptibility. 20 Another recently published associated SNP located in the ABO gene was rs687289, which was identified by GTEx functional prediction. 21 However, our linkage disequilibrium (LD) analysis showed that SLC2A6 rs3124761 was in low LD with any of the three ABO SNP previously reported.
The second genetic variant rs17458086 is located in the intron of SLC2A13 on Chr12q12. We found, for the first time, that carriers of the SLC2A13 rs17458086 C allele had a 1.38-fold increased
PanC risk compared with TT carriers. The change from T allele to C allele is predicted to reduce the DNA-binding ability with the BCL2 motif. Therefore, SLC2A13 expression should be increased when the BCL2 motif, which is predicted to suppress expression of the gene, binds to SLC2A13 rs17458086 C instead of the T allele. eQTL data further demonstrated that the substitution of rs17458086
T to C significantly enhanced the mRNA expression of SLC2A13.
In addition, we noticed that the frequency of the rare allele C of SLC2A13 rs17458086 was just above the level of the inclusive criteria (1.0%-1.6%), which reinforces that the functions of this class of subpolymorphic risk alleles (ie, those with rare risk allele frequencies 
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GLUT proteins in the digestive system serve as important mediators in maintaining normal functions, including the absorption of nutrients and ions, excretion of bile acids, and metabolism of toxins. [40] [41] [42] Dysregulation of the SLC2 gene is likely to be associated with carcinogenesis, tumor progression, metastasis, and chemoresistance.
Changes in expression and regulation of the GLUT family proteins, including GLUT13/HMIT, were observed in neoplasms of the digestive system and in breast cancer cells. 43, 44 Thus far, there are no detailed reports of biological functions of SLC2A6 in human cells.
As for SLC2A13, it is an H + /myoinositol symporter, whereas all of the other members of the GLUT family are facilitative transporters.
There are neither reported data about glucose transport activity for GLUT13/HMIT, nor any available information about the expression of the facilitative glucose transporter family in cancer. 37 Genetic alterations of SLC2A13 were observed to be prevalent in the early stage of lung cancer in Serbians, suggesting that structural changes of SLC2A13 could play a role in the development of non-small cell lung cancer.
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Additionally, several SNP in SLC2A13 were found to be closely related to Parkinson's disease independently or dependently at a genome-wide significance level. 46 ,47 SLC5A3 encodes a sodium myoinositol transporter involved in the response to hyperosmotic stress, and the sequence of SLC5A3 lies completely within that of MRPS6 that encodes a subunit of the mitochondrial ribosome.
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SLC5A3/MRPS6 rs9982601 was previously identified to have a genome-wide association with early-onset myocardial infarction.
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This SNP was also found to be associated with mRNA expression of MRPS6 in blood, with the risk C allele correlated with an increased mRNA expression. 48 We observed, for the first time, that the SLC5A3 rs1630747 C allele was associated with a reduced
PanC risk compared with the corresponding wild-type allele.
However, the eQTL data did not show any difference in mRNA expression levels between the two alleles, and we did not find any other available dataset from either GTXe or TCGA databases for further analysis. Therefore, the functional relevance of this SNP remains unknown.
However, we failed to identify any variants in the NRF2 gene to be associated with PanC risk. 
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